Full-Time

Health Outcomes Liaison/Senior Health Outcomes Liaison

Field Medical Affairs

Posted on 1/2/2025

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Compensation Overview

$170k - $205k/yr

+ Annual Bonus + Equity

Senior

New York, NY, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • PhD, PharmD, MD, or DO preferred. Candidates with a Master’s degree and significant relevant experience will also be considered
  • A minimum of 5 years of experience in a field based managed care, health outcomes role, or a hybrid HOL/payer role, or has a combination of industry & other payer related experience
  • Health outcomes, pharmaco-economics, population-based health management knowledge
Responsibilities
  • Communicate the clinical, economic, and humanistic value proposition of Axsome’s portfolio of products, in a fair and balanced manner, using approved resources, to healthcare population health decision makers including Pharmacy Directors, Medical Directors, Case Managers, Clinical Pharmacists, Formulary Decision Makers, etc. within payer organizations and to managed care professionals to ensure access to Axsome medications and improve patient outcomes
  • Collaborate closely with HEOR Strategy team, market access and other internal teams in development and execution of field-based tools
  • Compliantly coordinate activities with market access field team to ensure compliant and aligned account support
  • Identify opportunities to work with payers, academic institutions, and individuals to discuss research and facilitate initiation of HEOR research and evidence gap studies as aligned with strategy
  • Demonstrate leadership in area of evidence-based medicine and provide training and information to Field Medical and other functions as requested
  • Attend and provide support at relevant national and regional conferences throughout the year
  • Exchange information with population health decision makers and collect, synthesize and communicate actionable insights to internal stakeholders in order to help shape strategy and tactics
  • Be a Field therapeutic area expert demonstrating high scientific knowledge and competency in relevant therapeutic areas
Desired Qualifications
  • Experience working in CNS Therapeutic areas preferred
  • Strong knowledge of health economics outcomes research methodologies, and health policy
  • Experience with Payors, IDNs, GPOs and Government Programs preferred
  • Demonstrates in-depth understanding of the US Healthcare system and healthcare policy
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, agitation from Alzheimer's disease, migraine, narcolepsy, fibromyalgia, and smoking cessation. Their main product, AXS-05, is an oral medication that acts as an NMDA receptor antagonist, blocking brain receptors involved in mood regulation. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Axsome stands out from competitors by concentrating on unmet medical needs in CNS disorders and advancing its drug pipeline through thorough clinical trials. The company's goal is to bring effective treatments to market to enhance patient outcomes and quality of life.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Axsome's AXS-07 is anticipated to launch for migraines in 2025.
  • Investments from major firms indicate strong market confidence in Axsome.
  • EMA initiatives may expedite Axsome's entry into the European market.

What critics are saying

  • Increased competition in CNS disorder treatments may impact Axsome's market share.
  • Potential delays in clinical trials could postpone new product launches.
  • Dependence on AXS-05 and AXS-07 could affect financial performance if setbacks occur.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders with limited current treatment options.
  • AXS-05 has FDA Breakthrough Therapy Designation for major depressive disorder.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Clival
Apr 8th, 2025
Axsome to Present Positive Phase 3 AXS-05 & AXS-12 Results at AAN 2025

Axsome Therapeutics, Inc., a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, announced multiple presentations spanning its innovative, industry-leading psychiatry and neurology portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting, being held April 5-9 in San Diego, California.

Insider Monkey
Feb 23rd, 2025
Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma stock So Far in 2025.

Investing.com
Dec 19th, 2024
Amgen stock touches 52-week low at $257.77 amid market shifts

The firm sees potential in Sarepta's Elevidys for Duchenne muscular dystrophy, Legend's ability to double its manufacturing capacity, and Axsome's anticipated launch of AXS-07 for migraines.

MarketBeat
Dec 13th, 2024
Captrust Financial Advisors Invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 4th, 2024
Erste Asset Management GmbH Invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Erste Asset Management GmbH invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

INACTIVE